Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Irinotecan hydrochloride
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Irinotecan 100mg/5ml solution for infusion vials
0801050Q0AAAAAA
|
Irinotecan hydrochloride | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Irinotecan 300mg/15ml solution for infusion vials
0801050Q0AAACAC
|
Irinotecan hydrochloride | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Irinotecan 40mg/2ml solution for infusion vials
0801050Q0AAABAB
|
Irinotecan hydrochloride | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Irinotecan 500mg/25ml solution for infusion vials
0801050Q0AAADAD
|
Irinotecan hydrochloride | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Irinotecan pegylated liposomal 43mg/10ml inf vials
0801050Q0AAAEAE
|
Irinotecan hydrochloride | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.